It is well known how important feasibility reports are for timely enrollment and successful conduct of a study. We use our local knowledge and expertise in site selection to evaluate all aspects of your proposed study, including regulatory issues, epidemiology, limitations of enrollment, challenges with logistics, support with the importation of different clinical trial materials and timelines for approval by regulatory authorities.

To obtain reliable perspectives on the study, our feasibility approach builds on personal relationships and communication with Principle Investigators and Key Opinion Leaders (KOLs), rather than on generic distribution of questionnaires. We have excellent personal contacts with a significant number of opinion leaders and scientific experts who are willing to act as Principal Investigators and/or as members of Scientific Advisory Boards for our clinical trials. Our well-established relationships with local medical communities give us direct access to key scientists at principal clinical research centers across our jurisdictions.

Cromos personnel have experience in the organization of protocol draft review by local key opinion leaders, which allows our clients to obtain independent feedback from scientific and practical points of view at an early stage of protocol development. Additionally, we use "the closed cycle" for the start-up process in our company: on a regular basis we involve Clinical Operation teams, Regulatory Managers and medical writers for comprehensive capability/feasibility assessment. Establishing early and in-depth contributions from all our departments in the process of protocol development adds significant value at later stages in the study.

We strongly believe that careful selection and evaluation of Investigators is critical to the successful enrollment and quality of our studies. Consequently, we have created a sophisticated database of potential Investigators in addition to implementing a proprietary system to evaluate their performance at the end of each study.

What differentiates Cromosfrom our competitors is a unique method of site selection that is based on:

  • Experience with more than 800 sites in most therapeutic areas since 2004
  • Electronic Internal Investigators/Sites database (detailed contact information for 2,109 Investigators and 1,711 Study Sites)
  • Long-established operating activities in Central and Eastern Europe (Bulgaria, Croatia, Czech Republic, Estonia, Latvia, Lithuania, Hungary, Poland, Romania, Slovakia, Slovenia) and post-Soviet region (Russia, Ukraine, Georgia, Belarus, Armenia, Moldova, Kazakhstan, Uzbekistan)
  • Collaboration with validated partners in North and South America regions
  • Proprietary and customizable Electronic Feasibility Questionnaire
  • Investment into long-term relationship with investigators
  • Active consultations with country-specific key opinion leaders
  • Working with leading medical centers and tertiary hospitals guarantees high quality of clinical research and rapid recruitment
  • Mapping of competitive trials helps avoid slow recruitment

If you would like to conduct a feasibility or capability study, just contact our Head of Feasibility Division Dr. Serge Lomovskikh.